Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk prostate cancer.
Statcast has plenty of metrics to sort through when preparing for the fantasy baseball season, but one of my favorites is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results